Supplemental material - Cloud Object Storage | Store ...



Supplemental materialEstimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer contextPeter P. Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira and Jeroen P JansenSupplemental Table 1. CV event hospitalization diagnosis codes.CV eventType of codeCodesMIICD-10I21.x or I22.xUAICD-10I20.0, I20.9, I24.0, I24.8, or I24.9ISICD-10I63.xHFICD-10I11.0, I13.0, I13.2, or I50.xCoronary revascularizationOPCS-4K40-K46, K49, K50, or K75CV-related deathICD-10I00-I78CV, cardiovascular; HF, heart failure; ICD-10, International Classification of Diseases, Tenth Revision; IS, ischemic stroke; MI, myocardial infarction; OPCS, Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures, 4th Revision; UA, unstable angina.Supplemental Table 2. FOURIER baseline characteristics from design and methods article.CharacteristicAll randomized subjects(N = 27,564)Age, years, mean (SD)62.5 (9.0)Sex, male, n (%)20,795 (75.4)Race, n (%)White23,426 (85.0)Black or African American699 (2.4)Asian or other3439 (12.5)Region, n (%)North America4571 (16.6)Europe17,335 (62.9)Latin America1823 (6.6)Asia Pacific and South Africa3835 (13.9)Cardiovascular risk factors, n (%)Hypertension22,040 (80.0)Diabetes mellitus9333 (33.9)Current cigarette use7770 (28.2)History of vascular disease, n (%)MI22,356 (81.1)Nonhemorrhagic stroke5330 (19.3)Peripheral artery disease3640 (13.2)Statin use, n (%)High intensity19,082 (69.2)Moderate intensity8390 (30.4)Low intensity, unknown at this time, or no data92 (0.3)Ezetimibe use, n (%)1393 (5.1)Lipid parameters at parent study baseline, mg/dLLDL-C, median (Q1, Q3)91.5 (79.5, 108.0)LDL-C, mean (SD)97.3 (27.9)Total cholesterol, median (Q1, Q3)167.0 (150.5, 188.0)HDL-C, median (Q1, Q3)44.0 (37.0, 52.5)Triglycerides, median (Q1, Q3)133.0 (99.8, 181.0)Based on snapshot of database performed on October 2, 2015. Reprinted with permission from “Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial” PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYWJhdGluZTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+

PFJlY051bT4xOTwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIyc2VzenZkcG45OWRwdmV3OXJhNTk5dHR0emQ1NXRlc3RlcDkiPjE5PC9rZXk+PC9mb3Jl

aWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxj

b250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYWJhdGluZSwgTS4gUy48L2F1dGhvcj48YXV0

aG9yPkdpdWdsaWFubywgUi4gUC48L2F1dGhvcj48YXV0aG9yPktlZWNoLCBBLjwvYXV0aG9yPjxh

dXRob3I+SG9uYXJwb3VyLCBOLjwvYXV0aG9yPjxhdXRob3I+V2FuZywgSC48L2F1dGhvcj48YXV0

aG9yPkxpdSwgVC48L2F1dGhvcj48YXV0aG9yPldhc3Nlcm1hbiwgUy4gTS48L2F1dGhvcj48YXV0

aG9yPlNjb3R0LCBSLjwvYXV0aG9yPjxhdXRob3I+U2V2ZXIsIFAuIFMuPC9hdXRob3I+PGF1dGhv

cj5QZWRlcnNlbiwgVC4gUi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgt

YWRkcmVzcz5USU1JIFN0dWR5IEdyb3VwLCBEaXZpc2lvbiBvZiBDYXJkaW92YXNjdWxhciBNZWRp

Y2luZSwgQnJpZ2hhbSBhbmQgV29tZW4mYXBvcztzIEhvc3BpdGFsIGFuZCBIYXJ2YXJkIE1lZGlj

YWwgU2Nob29sLCBCb3N0b24sIE1BLiYjeEQ7U3lkbmV5IE1lZGljYWwgU2Nob29sLCBOSE1SQyBD

bGluaWNhbCBUcmlhbHMgQ2VudHJlLCBVbml2ZXJzaXR5IG9mIFN5ZG5leSwgQXVzdHJhbGlhLiYj

eEQ7QW1nZW4sIFRob3VzYW5kIE9ha3MsIENBLiYjeEQ7SW50ZXJuYXRpb25hbCBDZW50cmUgZm9y

IENpcmN1bGF0b3J5IEhlYWx0aCwgSW1wZXJpYWwgQ29sbGVnZSBMb25kb24sIExvbmRvbiwgVW5p

dGVkIEtpbmdkb20uJiN4RDtPc2xvIFVuaXZlcnNpdHkgSG9zcGl0YWwsIFVsbGV2YWwgYW5kIE1l

ZGljYWwgRmFjdWx0eSwgVW5pdmVyc2l0eSBvZiBPc2xvLCBPc2xvLCBOb3J3YXkuPC9hdXRoLWFk

ZHJlc3M+PHRpdGxlcz48dGl0bGU+UmF0aW9uYWxlIGFuZCBkZXNpZ24gb2YgdGhlIEZ1cnRoZXIg

Y2FyZGlvdmFzY3VsYXIgT1V0Y29tZXMgUmVzZWFyY2ggd2l0aCBQQ1NLOSBJbmhpYml0aW9uIGlu

IHN1YmplY3RzIHdpdGggRWxldmF0ZWQgUmlzayB0cmlhbDwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5BbSBIZWFydCBKPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+QW0gSGVhcnQgSjwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjk0LTEwMTwv

cGFnZXM+PHZvbHVtZT4xNzM8L3ZvbHVtZT48a2V5d29yZHM+PGtleXdvcmQ+QW50aWJvZGllcywg

TW9ub2Nsb25hbC8qYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3Jk

PkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FyZGlvdmFzY3VsYXIg

RGlzZWFzZXMvYmxvb2QvZXBpZGVtaW9sb2d5LypwcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tl

eXdvcmQ+PGtleXdvcmQ+Q2hvbGVzdGVyb2wsIFZMREwvKmJsb29kL2RydWcgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5Eb3NlLVJlc3BvbnNlIFJlbGF0aW9uc2hpcCwgRHJ1Zzwva2V5d29yZD48

a2V5d29yZD5Eb3VibGUtQmxpbmQgTWV0aG9kPC9rZXl3b3JkPjxrZXl3b3JkPkRydWcgQWRtaW5p

c3RyYXRpb24gU2NoZWR1bGU8L2tleXdvcmQ+PGtleXdvcmQ+RHJ1ZyBUaGVyYXB5LCBDb21iaW5h

dGlvbjwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJp

dGFpbi9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZHJveHltZXRoeWxnbHV0YXJ5bC1Db0EgUmVkdWN0YXNlIEluaGliaXRvcnMvKmFkbWlu

aXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdv

cmQ+PGtleXdvcmQ+SW5qZWN0aW9ucywgU3ViY3V0YW5lb3VzPC9rZXl3b3JkPjxrZXl3b3JkPkxp

cG9wcm90ZWlucywgTERMLypibG9vZC9kcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWFs

ZTwva2V5d29yZD48a2V5d29yZD5Ob3J3YXkvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByb3Byb3RlaW4gQ29udmVydGFzZXMvKmFudGFnb25pc3RzICZhbXA7IGluaGliaXRvcnM8L2tl

eXdvcmQ+PGtleXdvcmQ+KlJpc2sgQXNzZXNzbWVudDwva2V5d29yZD48a2V5d29yZD5SaXNrIEZh

Y3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U2VyaW5lIEVuZG9wZXB0aWRhc2VzPC9rZXl3b3JkPjxr

ZXl3b3JkPlN1cnZpdmFsIFJhdGUvdHJlbmRzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBP

dXRjb21lPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBTdGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5N

YXI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xMDk3LTY3NDQgKEVsZWN0cm9uaWMp

JiN4RDswMDAyLTg3MDMgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2OTIwNjAxPC9h

Y2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5s

bS5uaWguZ292L3B1Ym1lZC8yNjkyMDYwMTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxl

Y3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmFoai4yMDE1LjExLjAxNTwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYWJhdGluZTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+

PFJlY051bT4xOTwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIyc2VzenZkcG45OWRwdmV3OXJhNTk5dHR0emQ1NXRlc3RlcDkiPjE5PC9rZXk+PC9mb3Jl

aWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxj

b250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYWJhdGluZSwgTS4gUy48L2F1dGhvcj48YXV0

aG9yPkdpdWdsaWFubywgUi4gUC48L2F1dGhvcj48YXV0aG9yPktlZWNoLCBBLjwvYXV0aG9yPjxh

dXRob3I+SG9uYXJwb3VyLCBOLjwvYXV0aG9yPjxhdXRob3I+V2FuZywgSC48L2F1dGhvcj48YXV0

aG9yPkxpdSwgVC48L2F1dGhvcj48YXV0aG9yPldhc3Nlcm1hbiwgUy4gTS48L2F1dGhvcj48YXV0

aG9yPlNjb3R0LCBSLjwvYXV0aG9yPjxhdXRob3I+U2V2ZXIsIFAuIFMuPC9hdXRob3I+PGF1dGhv

cj5QZWRlcnNlbiwgVC4gUi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgt

YWRkcmVzcz5USU1JIFN0dWR5IEdyb3VwLCBEaXZpc2lvbiBvZiBDYXJkaW92YXNjdWxhciBNZWRp

Y2luZSwgQnJpZ2hhbSBhbmQgV29tZW4mYXBvcztzIEhvc3BpdGFsIGFuZCBIYXJ2YXJkIE1lZGlj

YWwgU2Nob29sLCBCb3N0b24sIE1BLiYjeEQ7U3lkbmV5IE1lZGljYWwgU2Nob29sLCBOSE1SQyBD

bGluaWNhbCBUcmlhbHMgQ2VudHJlLCBVbml2ZXJzaXR5IG9mIFN5ZG5leSwgQXVzdHJhbGlhLiYj

eEQ7QW1nZW4sIFRob3VzYW5kIE9ha3MsIENBLiYjeEQ7SW50ZXJuYXRpb25hbCBDZW50cmUgZm9y

IENpcmN1bGF0b3J5IEhlYWx0aCwgSW1wZXJpYWwgQ29sbGVnZSBMb25kb24sIExvbmRvbiwgVW5p

dGVkIEtpbmdkb20uJiN4RDtPc2xvIFVuaXZlcnNpdHkgSG9zcGl0YWwsIFVsbGV2YWwgYW5kIE1l

ZGljYWwgRmFjdWx0eSwgVW5pdmVyc2l0eSBvZiBPc2xvLCBPc2xvLCBOb3J3YXkuPC9hdXRoLWFk

ZHJlc3M+PHRpdGxlcz48dGl0bGU+UmF0aW9uYWxlIGFuZCBkZXNpZ24gb2YgdGhlIEZ1cnRoZXIg

Y2FyZGlvdmFzY3VsYXIgT1V0Y29tZXMgUmVzZWFyY2ggd2l0aCBQQ1NLOSBJbmhpYml0aW9uIGlu

IHN1YmplY3RzIHdpdGggRWxldmF0ZWQgUmlzayB0cmlhbDwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5BbSBIZWFydCBKPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+QW0gSGVhcnQgSjwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjk0LTEwMTwv

cGFnZXM+PHZvbHVtZT4xNzM8L3ZvbHVtZT48a2V5d29yZHM+PGtleXdvcmQ+QW50aWJvZGllcywg

TW9ub2Nsb25hbC8qYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3Jk

PkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FyZGlvdmFzY3VsYXIg

RGlzZWFzZXMvYmxvb2QvZXBpZGVtaW9sb2d5LypwcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tl

eXdvcmQ+PGtleXdvcmQ+Q2hvbGVzdGVyb2wsIFZMREwvKmJsb29kL2RydWcgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5Eb3NlLVJlc3BvbnNlIFJlbGF0aW9uc2hpcCwgRHJ1Zzwva2V5d29yZD48

a2V5d29yZD5Eb3VibGUtQmxpbmQgTWV0aG9kPC9rZXl3b3JkPjxrZXl3b3JkPkRydWcgQWRtaW5p

c3RyYXRpb24gU2NoZWR1bGU8L2tleXdvcmQ+PGtleXdvcmQ+RHJ1ZyBUaGVyYXB5LCBDb21iaW5h

dGlvbjwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJp

dGFpbi9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZHJveHltZXRoeWxnbHV0YXJ5bC1Db0EgUmVkdWN0YXNlIEluaGliaXRvcnMvKmFkbWlu

aXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdv

cmQ+PGtleXdvcmQ+SW5qZWN0aW9ucywgU3ViY3V0YW5lb3VzPC9rZXl3b3JkPjxrZXl3b3JkPkxp

cG9wcm90ZWlucywgTERMLypibG9vZC9kcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWFs

ZTwva2V5d29yZD48a2V5d29yZD5Ob3J3YXkvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByb3Byb3RlaW4gQ29udmVydGFzZXMvKmFudGFnb25pc3RzICZhbXA7IGluaGliaXRvcnM8L2tl

eXdvcmQ+PGtleXdvcmQ+KlJpc2sgQXNzZXNzbWVudDwva2V5d29yZD48a2V5d29yZD5SaXNrIEZh

Y3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U2VyaW5lIEVuZG9wZXB0aWRhc2VzPC9rZXl3b3JkPjxr

ZXl3b3JkPlN1cnZpdmFsIFJhdGUvdHJlbmRzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBP

dXRjb21lPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBTdGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5N

YXI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xMDk3LTY3NDQgKEVsZWN0cm9uaWMp

JiN4RDswMDAyLTg3MDMgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2OTIwNjAxPC9h

Y2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5s

bS5uaWguZ292L3B1Ym1lZC8yNjkyMDYwMTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxl

Y3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmFoai4yMDE1LjExLjAxNTwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [1]. ? 2016 Elsevier.HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol, MI, myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9; Q1, first quartile; Q3, third quartile; SD, standard deviation.Supplemental Table 3. Cost-effectiveness model input: CV event rates and clinical characteristics of patients on SOC alone used in the cost-effectiveness model.aCohortHistory of CV events at baselineAge at baseline, yearsbLDL-C at baseline, mmol/LEvent countcPatient-yearsRate per 100 patient-years (SE)cPAD12%692.841191930.36.17 (0.57)ACS0%692.84125491.725.42 (2.27)Post-ACS71%86854.110.07 (1.09)IS0%702.7117132.812.80 (3.10)Post-IS17%27238.511.32 (2.18)HF0%702.5576232.132.75 (3.76)Post-HF0%45397.411.32 (1.69)aIn the model, rates were adjusted by age using a rate ratio of 1.03 per year (estimated from pooling data across the cohorts in this table).bIn the model, rates were adjusted by LDL-C levels using a rate ratio of 0.79 per mmol/L PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DaG9sZXN0ZXJvbCBUcmVhdG1lbnQgVHJpYWxpc3RzIChD

VFQpIENvbGxhYm9yYXRpb248L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxSZWNOdW0+OTwvUmVj

TnVtPjxEaXNwbGF5VGV4dD5bMl08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+OTwv

cmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJzZXN6dmRwbjk5

ZHB2ZXc5cmE1OTl0dHR6ZDU1dGVzdGVwOSI+OTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlw

ZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo

b3JzPjxhdXRob3I+Q2hvbGVzdGVyb2wgVHJlYXRtZW50IFRyaWFsaXN0cyAoQ1RUKSBDb2xsYWJv

cmF0aW9uLDwvYXV0aG9yPjxhdXRob3I+RnVsY2hlciwgSi48L2F1dGhvcj48YXV0aG9yPk8mYXBv

cztDb25uZWxsLCBSLjwvYXV0aG9yPjxhdXRob3I+Vm95c2V5LCBNLjwvYXV0aG9yPjxhdXRob3I+

RW1iZXJzb24sIEouPC9hdXRob3I+PGF1dGhvcj5CbGFja3dlbGwsIEwuPC9hdXRob3I+PGF1dGhv

cj5NaWhheWxvdmEsIEIuPC9hdXRob3I+PGF1dGhvcj5TaW1lcywgSi48L2F1dGhvcj48YXV0aG9y

PkNvbGxpbnMsIFIuPC9hdXRob3I+PGF1dGhvcj5LaXJieSwgQS48L2F1dGhvcj48YXV0aG9yPkNv

bGhvdW4sIEguPC9hdXRob3I+PGF1dGhvcj5CcmF1bndhbGQsIEUuPC9hdXRob3I+PGF1dGhvcj5M

YSBSb3NhLCBKLjwvYXV0aG9yPjxhdXRob3I+UGVkZXJzZW4sIFQuIFIuPC9hdXRob3I+PGF1dGhv

cj5Ub25raW4sIEEuPC9hdXRob3I+PGF1dGhvcj5EYXZpcywgQi48L2F1dGhvcj48YXV0aG9yPlNs

ZWlnaHQsIFAuPC9hdXRob3I+PGF1dGhvcj5GcmFuem9zaSwgTS4gRy48L2F1dGhvcj48YXV0aG9y

PkJhaWdlbnQsIEMuPC9hdXRob3I+PGF1dGhvcj5LZWVjaCwgQS48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+RWZmaWNhY3kgYW5kIHNhZmV0eSBvZiBMREwt

bG93ZXJpbmcgdGhlcmFweSBhbW9uZyBtZW4gYW5kIHdvbWVuOiBtZXRhLWFuYWx5c2lzIG9mIGlu

ZGl2aWR1YWwgZGF0YSBmcm9tIDE3NCwwMDAgcGFydGljaXBhbnRzIGluIDI3IHJhbmRvbWlzZWQg

dHJpYWxzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkxhbmNldDwvc2Vjb25kYXJ5LXRpdGxlPjwv

dGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkxhbmNldDwvZnVsbC10aXRsZT48L3Blcmlv

ZGljYWw+PHBhZ2VzPjEzOTctNDA1PC9wYWdlcz48dm9sdW1lPjM4NTwvdm9sdW1lPjxudW1iZXI+

OTk3NjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5DYXJkaW92YXNjdWxhciBEaXNlYXNlcy8q

cHJldmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkNob2xlc3Rlcm9sLCBM

REwvKmJsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkNvcm9uYXJ5IERpc2Vhc2UvcHJldmVudGlvbiAm

YW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkRhdGFiYXNlcywgRmFjdHVhbDwva2V5d29y

ZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZHJveHltZXRoeWxnbHV0YXJ5bC1Db0EgUmVkdWN0YXNlIEluaGliaXRvcnMvYWRtaW5p

c3RyYXRpb24gJmFtcDs8L2tleXdvcmQ+PGtleXdvcmQ+ZG9zYWdlLyp0aGVyYXBldXRpYyB1c2U8

L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5QZXJjdXRhbmVvdXMgQ29y

b25hcnkgSW50ZXJ2ZW50aW9uL3N0YXRpc3RpY3MgJmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdv

cmQ+PGtleXdvcmQ+UHJvcG9ydGlvbmFsIEhhemFyZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3Jk

PlNleCBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlN0cm9rZS9wcmV2ZW50aW9uICZhbXA7IGNv

bnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+VHJlYXRtZW50IE91dGNvbWU8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkFwciAxMTwvZGF0

ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE0NzQtNTQ3WCAoRWxlY3Ryb25pYykmI3hEOzAx

NDAtNjczNiAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjU1Nzk4MzQ8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzI1NTc5ODM0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDE2L1MwMTQwLTY3MzYoMTQpNjEzNjgtNDwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DaG9sZXN0ZXJvbCBUcmVhdG1lbnQgVHJpYWxpc3RzIChD

VFQpIENvbGxhYm9yYXRpb248L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxSZWNOdW0+OTwvUmVj

TnVtPjxEaXNwbGF5VGV4dD5bMl08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+OTwv

cmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJzZXN6dmRwbjk5

ZHB2ZXc5cmE1OTl0dHR6ZDU1dGVzdGVwOSI+OTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlw

ZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo

b3JzPjxhdXRob3I+Q2hvbGVzdGVyb2wgVHJlYXRtZW50IFRyaWFsaXN0cyAoQ1RUKSBDb2xsYWJv

cmF0aW9uLDwvYXV0aG9yPjxhdXRob3I+RnVsY2hlciwgSi48L2F1dGhvcj48YXV0aG9yPk8mYXBv

cztDb25uZWxsLCBSLjwvYXV0aG9yPjxhdXRob3I+Vm95c2V5LCBNLjwvYXV0aG9yPjxhdXRob3I+

RW1iZXJzb24sIEouPC9hdXRob3I+PGF1dGhvcj5CbGFja3dlbGwsIEwuPC9hdXRob3I+PGF1dGhv

cj5NaWhheWxvdmEsIEIuPC9hdXRob3I+PGF1dGhvcj5TaW1lcywgSi48L2F1dGhvcj48YXV0aG9y

PkNvbGxpbnMsIFIuPC9hdXRob3I+PGF1dGhvcj5LaXJieSwgQS48L2F1dGhvcj48YXV0aG9yPkNv

bGhvdW4sIEguPC9hdXRob3I+PGF1dGhvcj5CcmF1bndhbGQsIEUuPC9hdXRob3I+PGF1dGhvcj5M

YSBSb3NhLCBKLjwvYXV0aG9yPjxhdXRob3I+UGVkZXJzZW4sIFQuIFIuPC9hdXRob3I+PGF1dGhv

cj5Ub25raW4sIEEuPC9hdXRob3I+PGF1dGhvcj5EYXZpcywgQi48L2F1dGhvcj48YXV0aG9yPlNs

ZWlnaHQsIFAuPC9hdXRob3I+PGF1dGhvcj5GcmFuem9zaSwgTS4gRy48L2F1dGhvcj48YXV0aG9y

PkJhaWdlbnQsIEMuPC9hdXRob3I+PGF1dGhvcj5LZWVjaCwgQS48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+RWZmaWNhY3kgYW5kIHNhZmV0eSBvZiBMREwt

bG93ZXJpbmcgdGhlcmFweSBhbW9uZyBtZW4gYW5kIHdvbWVuOiBtZXRhLWFuYWx5c2lzIG9mIGlu

ZGl2aWR1YWwgZGF0YSBmcm9tIDE3NCwwMDAgcGFydGljaXBhbnRzIGluIDI3IHJhbmRvbWlzZWQg

dHJpYWxzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkxhbmNldDwvc2Vjb25kYXJ5LXRpdGxlPjwv

dGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkxhbmNldDwvZnVsbC10aXRsZT48L3Blcmlv

ZGljYWw+PHBhZ2VzPjEzOTctNDA1PC9wYWdlcz48dm9sdW1lPjM4NTwvdm9sdW1lPjxudW1iZXI+

OTk3NjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5DYXJkaW92YXNjdWxhciBEaXNlYXNlcy8q

cHJldmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkNob2xlc3Rlcm9sLCBM

REwvKmJsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkNvcm9uYXJ5IERpc2Vhc2UvcHJldmVudGlvbiAm

YW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkRhdGFiYXNlcywgRmFjdHVhbDwva2V5d29y

ZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZHJveHltZXRoeWxnbHV0YXJ5bC1Db0EgUmVkdWN0YXNlIEluaGliaXRvcnMvYWRtaW5p

c3RyYXRpb24gJmFtcDs8L2tleXdvcmQ+PGtleXdvcmQ+ZG9zYWdlLyp0aGVyYXBldXRpYyB1c2U8

L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5QZXJjdXRhbmVvdXMgQ29y

b25hcnkgSW50ZXJ2ZW50aW9uL3N0YXRpc3RpY3MgJmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdv

cmQ+PGtleXdvcmQ+UHJvcG9ydGlvbmFsIEhhemFyZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3Jk

PlNleCBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlN0cm9rZS9wcmV2ZW50aW9uICZhbXA7IGNv

bnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+VHJlYXRtZW50IE91dGNvbWU8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkFwciAxMTwvZGF0

ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE0NzQtNTQ3WCAoRWxlY3Ryb25pYykmI3hEOzAx

NDAtNjczNiAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjU1Nzk4MzQ8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzI1NTc5ODM0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDE2L1MwMTQwLTY3MzYoMTQpNjEzNjgtNDwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [2].cCounts and rates include ACS, IS, HF, and CV death.ACS, acute coronary syndrome; CV, cardiovascular; HF, heart failure; IS, ischemic stroke; LDL-C, low-density lipoprotein-cholesterol; PAD, peripheral artery disease; SE, standard error; SOC, standard of care.Supplemental Table 4. CV event rates with EvoMab added to SOC vs SOC alone.Health stateBaseline LDL-C ≥?70?mg/dLBaseline LDL-C ≥?100?mg/dLEvoMab+ SOC, rateSOC, rateIncre, rate% change% change per mmol/LEvoMab+ SOC, rateSOC, rateIncre, rate% change% change per mmol/LACS0.831.25?0.43?34?260.841.43?0.60?42?26IS0.090.13?0.04?33?250.090.15?0.06?40?25HF0.100.18?0.07?41?320.110.21?0.10?50?32CV-related death0.450.53?0.09?16?120.470.59?0.12?20?12Revascularization0.891.42?0.52?37?290.831.51?0.67?45?28Major CV event1.361.92?0.56?29?221.402.17?0.77?36?22ACS, acute coronary syndrome; CV, cardiovascular; EvoMab, evolocumab; HF, heart failure; incre, incremental; IS, ischemic stroke; LDL-C, low-density lipoprotein-cholesterol; SOC, standard of care. References ADDIN EN.REFLIST 1.Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94-101.2.Cholesterol Treatment Trialists (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download